# Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis

> **NCT06850727** · PHASE2 · RECRUITING · sponsor: **Odyssey Therapeutics** · enrollment: 57 (estimated)

## Conditions studied

- Ulcerative Colitis (UC)
- UC - Ulcerative Colitis

## Interventions

- **DRUG:** OD-07656
- **DRUG:** Vedolizumab

## Key facts

- **NCT ID:** NCT06850727
- **Lead sponsor:** Odyssey Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-02
- **Primary completion:** 2026-04
- **Final completion:** 2026-11
- **Target enrollment:** 57 (ESTIMATED)
- **Last updated:** 2026-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06850727

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06850727, "Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06850727. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*